In a previous blog post, we shared that the Pharmacy and Poisons Board updated the Guidelines for Establishment of Qualified Persons for Pharmacovigilance (QPPV). Well, since then, the pharmacovigilance environment in Kenya has been evolving rapidly, and for many pharmaceutical companies, compliance expectations are becoming more demanding than ever.
All Marketing Authorization Holders (MAHs) are now expected to demonstrate not only the appointment of a QPPV, but also the existence of a fully functional, compliant, and continuously maintained pharmacovigilance system.
For many organizations, this shift represents a major operational and regulatory challenge.
In the past, some companies viewed pharmacovigilance mainly as a post-registration obligation focused on adverse event reporting. Today, regulators expect MAHs to establish comprehensive systems capable of detecting, assessing, documenting, and managing medicine safety issues throughout the product lifecycle.
This means pharmacovigilance compliance is no longer simply about having a designated QPPV on file; it is about proving that the entire pharmacovigilance framework is active, effective, inspection-ready, and aligned with Kenyan regulatory requirements.
The Expanding Role of the QPPV in Kenya
One of the most significant developments introduced in the updated guideline is the strengthened role of the Qualified Person for Pharmacovigilance.
The QPPV is now expected to act on behalf of the MAH in pharmacovigilance matters, including communication and liaison with the Board. This places greater accountability on both the MAH and the appointed QPPV.
In practical terms, the QPPV is expected to oversee:
- Maintenance of the Pharmacovigilance System Master File (PSMF)
- Local safety reporting activities
- Compliance with reporting timelines
- Oversight of pharmacovigilance procedures
- Coordination of safety information
- Regulatory communication
- Inspection readiness
- Oversight of outsourced PV activities
- Continuous monitoring of the pharmacovigilance system
This expanded responsibility means companies must ensure that their QPPV has adequate local oversight, access to safety data, and sufficient operational support to fulfil these obligations effectively.
Why Many Companies Are Struggling with Compliance
As regulatory expectations continue to grow, many MAHs are finding it difficult to maintain fully compliant pharmacovigilance systems, especially when operating across multiple African markets.
Some of the most common challenges include:
1. Incomplete or Outdated PSMFs
The Pharmacovigilance System Master File remains one of the most important compliance documents for any MAH. However, many companies still struggle with:
- Missing procedural information
- Inconsistent organizational structures
- Outdated vendor information
- Lack of documentation for local PV activities
- Poor alignment between SOPs and actual practices
An outdated PSMF can quickly become a major compliance risk during inspections or regulatory reviews.
2. Limited Local Pharmacovigilance Oversight
The updated Kenyan guideline clearly emphasises local oversight requirements, including that both the QPPV and the back-up QPPV must reside in Kenya.
For foreign MAHs or companies managing multiple territories remotely, maintaining effective local oversight can be particularly challenging without a reliable local pharmacovigilance partner.
3. Ineffective Adverse Event Reporting Processes
A compliant pharmacovigilance system depends heavily on timely and accurate safety reporting.
However, many organizations continue to face difficulties such as:
- Delayed case reporting
- Lack of trained personnel
- Poor documentation practices
- Weak communication channels between distributors, healthcare professionals, and MAHs
- Inadequate follow-up procedures for safety cases
Even small delays or documentation gaps can create serious regulatory concerns over time.
4. Challenges With Outsourced PV Activities
Many MAHs outsource pharmacovigilance responsibilities to third-party service providers. While outsourcing can improve efficiency, it does not remove the MAH’s regulatory responsibility.
The updated guideline also introduced limits on outsourced QPPV coverage, stating that a nominated QPPV shall support not more than five companies.
This means MAHs must now conduct greater due diligence when selecting local pharmacovigilance partners and ensure:
- Clear contractual agreements are in place
- Roles and responsibilities are well defined
- Oversight mechanisms are documented
- Service providers remain within regulatory thresholds
Inspection Readiness Is Becoming Increasingly Important
Across global and African regulatory systems, pharmacovigilance inspections are becoming more common and more detailed.
Kenya is no exception.
Regulators are increasingly focused on verifying whether MAHs can demonstrate actual implementation of pharmacovigilance obligations rather than simply providing documentation during submissions.
During inspections, authorities may review:
- PSMFs
- SOPs
- Safety reporting timelines
- Case processing workflows
- Training records
- Vendor qualification documents
- QPPV designation records
- Literature monitoring activities
- CAPA records
- Compliance metrics
- Archiving systems
Companies that fail to maintain proper documentation or oversight structures may face:
- Regulatory findings
- Delays in approvals or renewals
- Increased regulatory scrutiny
- Requests for corrective actions
- Potential business disruptions
For this reason, maintaining continuous inspection readiness is becoming essential rather than optional.
The Importance of Local Pharmacovigilance Expertise
Kenya remains one of the most important pharmaceutical markets in East Africa, and its pharmacovigilance requirements continue to mature in line with international regulatory expectations.
As a result, companies entering or operating within the Kenyan market increasingly require:
- Reliable local QPPV support
- Local regulatory expertise
- Strong pharmacovigilance infrastructure
- Ongoing compliance monitoring
- Regulatory intelligence support
Having experienced local pharmacovigilance professionals can significantly reduce compliance risks while improving communication with regulators and ensuring the timely execution of pharmacovigilance activities.
How Jeyflex Consultants Supports MAHs in Kenya
At Jeyflex Consultants Ltd., we work closely with pharmaceutical companies to strengthen pharmacovigilance compliance and support long-term regulatory success in Kenya.
Our services include:
- Local QPPV and back-up QPPV services
- PSMF preparation, review, and maintenance
- Literature screening/monitoring
- Case management services
- Periodic Safety Report Management (PSRs)
- Risk Management Plans(RMP)
- Signal Detection and Management
- Pharmacovigilance System Audits and Inspections
- SOP development and review
- PV training and compliance support
- Pharmacovigilance Regulatory Intelligence
We understand the practical challenges MAHs face when managing pharmacovigilance functions across multiple markets, and we provide tailored support designed to help companies maintain compliance while focusing on their core business operations.
Don’t Wait for a Regulatory Finding to Review Your Pharmacovigilance System
Many pharmacovigilance gaps remain unnoticed until:
- A regulatory inspection occurs
- A renewal application is submitted
- A serious adverse event is reported
- Authorities request additional documentation
- A compliance issue escalates unexpectedly
By then, resolving the issue can become far more difficult, time-consuming, and costly.
A proactive pharmacovigilance strategy helps protect not only regulatory compliance but also patient safety, product reputation, and business continuity.
Need Expert QPPV and Pharmacovigilance Support in Kenya?
We are ready to support your organisation. Contact us today to strengthen your pharmacovigilance system, maintain compliance, and stay inspection-ready in Kenya’s evolving regulatory environment.
Written by: Marraret Ouma